Trial · NCT06945848
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 14 of 14
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Rate of patients with normalization of intra-cranial pressure | 3 months | Rate of patients with normalization of intra-cranial pressure (defined as ≤ 25 cm H20 or 18 mmHg) |
| Secondary | Discontinuation of Acetazolamide | 1 month | Percentage of patients discontinuing ACZ in the stenting group without papillary edema recurrence |
| Secondary | Discontinuation of Acetazolamide | 3 months | Percentage of patients discontinuing ACZ in the stenting group without papillary edema recurrence |
| Secondary | Headache | 3 and 12 months | Change in mean HIT-6 grading scale score (patient's questionnaire containing 6 questions to evaluate the severity of headache) |
| Secondary | Monthly headache days | 3 and 12 months | Change in monthly headache days (within the last month) reported on patients' dairy |
| Secondary | Tinnitus | 3 and 12 months | Change in THI (Tinnitus Handicap Inventory) score |
| Secondary | Visual field | 3 and 12 months | Change in decibel of Mean Deficit visual field assessed on automated perimetry in both eyes with Humphrey Field Analyzer SITA Standard 24-2 test pattern. Each participant will have at least 2 initial visual field examinations conducted at least 30 minutes apart. The 2 Perimetric Mean Deviation (PMD) measurements will be averaged. |
| Secondary | Visual acuity | 3 and 12 months | Change of visual acuity score evaluated on ETDRS (far vision) at 4 meters and reproducible lighting using the best optical correction |
| Secondary | Visual acuity | 3 and 12 months | Change of visual acuity score evaluated on Parinaud scale (near vision) using the best optical correction |
| Secondary | Papilledema | 3 and 12 months | Change of papilledema assessed on Frisen score on OCT |
| Secondary | Papilledema | 3 and 12 months | Change of papilledema assessed on RNFL on OCT |
| Secondary | Patient's autonomy | 3 and 12 months | Change in quality of life assessed on EQ5D questionnaire |
| Secondary | Patient's cognition | 3 and 12 months | Change in Montreal Cognitive Assessment (MoCA) |
| Secondary | Cognition | 3 and 12 months | Change in Trail Making Test (TMT) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06945848/registered